X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs PANACEA BIOTECH - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD PANACEA BIOTECH WYETH LTD/
PANACEA BIOTECH
 
P/E (TTM) x 27.7 -6.3 - View Chart
P/BV x 5.3 1.9 286.2% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    WYETH LTD
Mar-13
PANACEA BIOTECH
Mar-14
WYETH LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,044149 702.4%   
Low Rs81882 993.9%   
Sales per share (Unadj.) Rs298.684.1 354.8%  
Earnings per share (Unadj.) Rs57.2-18.3 -312.7%  
Cash flow per share (Unadj.) Rs58.4-6.7 -872.0%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.583.7 298.0%  
Shares outstanding (eoy) m22.7261.25 37.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.11.4 227.2%   
Avg P/E ratio x16.3-6.3 -257.9%  
P/CF ratio (eoy) x15.9-17.2 -92.5%  
Price / Book Value ratio x3.71.4 270.5%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,1577,074 299.1%   
No. of employees `0000.52.8 17.9%   
Total wages/salary Rs m4001,449 27.6%   
Avg. sales/employee Rs Th13,787.41,874.1 735.7%   
Avg. wages/employee Rs Th813.0527.0 154.3%   
Avg. net profit/employee Rs Th2,643.3-407.7 -648.3%   
INCOME DATA
Net Sales Rs m6,7835,154 131.6%  
Other income Rs m353100 353.3%   
Total revenues Rs m7,1365,254 135.8%   
Gross profit Rs m1,617-766 -211.1%  
Depreciation Rs m27711 3.7%   
Interest Rs m61,503 0.4%   
Profit before tax Rs m1,938-2,881 -67.3%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-51,771 -0.3%   
Tax Rs m63217 3,763.1%   
Profit after tax Rs m1,301-1,121 -116.0%  
Gross profit margin %23.8-14.9 -160.3%  
Effective tax rate %32.6-0.6 -5,593.8%   
Net profit margin %19.2-21.8 -88.1%  
BALANCE SHEET DATA
Current assets Rs m6,9843,810 183.3%   
Current liabilities Rs m2,0568,365 24.6%   
Net working cap to sales %72.6-88.4 -82.2%  
Current ratio x3.40.5 745.8%  
Inventory Days Days99156 63.8%  
Debtors Days Days2467 35.6%  
Net fixed assets Rs m24414,480 1.7%   
Share capital Rs m22761 370.6%   
"Free" reserves Rs m5,441903 602.5%   
Net worth Rs m5,6685,127 110.5%   
Long term debt Rs m255,832 0.4%   
Total assets Rs m7,90119,433 40.7%  
Interest coverage x353.3-0.9 -38,551.8%   
Debt to equity ratio x01.1 0.4%  
Sales to assets ratio x0.90.3 323.7%   
Return on assets %16.52.0 841.6%  
Return on equity %22.9-21.9 -104.9%  
Return on capital %34.03.6 936.3%  
Exports to sales %0.224.5 0.9%   
Imports to sales %36.310.2 356.9%   
Exports (fob) Rs m151,264 1.2%   
Imports (cif) Rs m2,465525 469.8%   
Fx inflow Rs m151,539 1.0%   
Fx outflow Rs m2,677942 284.2%   
Net fx Rs m-2,662597 -445.7%   
CASH FLOW
From Operations Rs m923599 154.1%  
From Investments Rs m317-438 -72.4%  
From Financial Activity Rs m-481-303 159.0%  
Net Cashflow Rs m759-141 -537.2%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 0.6 1,883.3%  
FIIs % 7.2 1.3 553.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 23.6 128.8%  
Shareholders   21,978 10,259 214.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare WYETH LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WYETH LTD WITH

MARKET STATS